If you have been reading about NR1D1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== Fluorochemical manufacturing workers === People who work at fluorochemical production plants and in manufacturing industries that use PFAS in the industrial process can be exposed to PFAS in the workplace. Much of what we know about PFAS exposure and health effects began with medical surveillance studies of workers exposed to PFAS at fluorochemical production facilities. These studies began in the 1940s and were conducted primarily at U.S. and European manufacturing sites. Between the 1940s and 2000s, thousands of workers exposed to PFAS participated in research studies that advanced scientific understanding of exposure pathways, toxicokinetic properties, and adverse health effects associated with exposure. The first research study to report elevated organic fluorine levels in the blood of fluorochemical workers was published in 1980. It established inhalation as a potential route of occupational PFAS exposure by reporting measurable levels of organic fluorine in air samples at the facility. Workers at fluorochemical production facilities have higher levels of PFOA and PFOS in their blood than the general population. Serum PFOA levels in fluorochemical workers are generally below 20,000 ng/mL but have been reported as high as 100,000 ng/mL, whereas the mean PFOA concentration among non-occupationally exposed cohorts in the same time frame was 4.9 ng/mL. Among fluorochemical workers, those with direct contact with PFAS have higher PFAS concentrations in their blood than those with intermittent contact or no direct PFAS contact.
=== 18 April === Two people were killed in separate Russian attacks in Donetsk Oblast. Russia claimed to have shot down five Ukrainian balloons carrying explosives over Belgorod and Voronezh Oblasts. A Polish national was arrested in Poland on suspicion of spying for Russia as part of a plot to assassinate Zelenskyy during his visit there, following a tip from Ukrainian authorities. EU foreign policy chief Josep Borrell called on EU member states to send anti-missile systems to Ukraine.
The short length of pompilidotoxins implies that the crucial amino acid for receptor binding would be easier to detect in studies based on pompilidotoxins. Additionally, the binding of the α-scorpion or sea anemone toxin to the sodium receptor also includes a complex system of forming three to four additional disulfide bonds. Pompilidotoxins cannot form such bonds. Pompilidotoxins thus provide a special advantage to research, classify, and characterise different isoforms of sodium channels due to their concise and simple structure. They have already been used for neuronal research into the action mechanisms of sodium channels, and the characterisation of receptor functions. Knowing more about the working of sodium channels could greatly contribute to healthcare as sodium channel alterations are associated with a large range of neurological disorders. Persistent sodium currents are especially participating in some variants of epilepsy and MS. Moreover, β-PMTX itself has been associated with being an epilepsy-inducing agent due to its drastic working in increasing neuronal excitability and has been recognized as being especially important for providing insights into the role of sodium currents in epileptogenesis. Thus, even though pompilidotoxins are not used as drugs and therefore have no efficacious nor adverse effects, they are medically valuable as a research model to indirectly improve patient well-being.
=== Kidneys === The renal parenchyma is divided into two major structures: the outer renal cortex and the inner renal medulla. Grossly, these structures take the shape of 7 to 18 cone-shaped renal lobes, each containing renal cortex surrounding a portion of medulla called a renal pyramid.
Sources: en.wikipedia.org
=== Immune cells and inflammatory signaling === Macrophages present in the lesion environment differentiate into Multinucleated Giant Cells after prolonged activation. Secreted matrix metalloproteinases degrade collagen and fuel necrobiosis in response to immune activation. T cells, prominent in NL (Th-1 type cytokines) inhibit healing by the production of IFN-γ, suppressing M2 repair. These factors suggest a link to autoimmune conditions, as these factors explain a pro-inflammatory feedback loop.
=== Non-Levantine groups claiming Israelite ancestry === Largely owing to the spread of Christianity and Islam globally, several groups of people outside of the Levant have claimed Israelite ancestry on an ethnic or racial basis. These various non-Levantine groups include Mandaeans, Pashtuns, British Israelists, Black Hebrew Israelites, Igbos, Mormons, and the Christian Identity movement. The phenomenon became especially prevalent after the founding of the State of Israel in 1948, as the country's Law of Return grants citizenship to qualified Jews and to non-Jews who are either married to a Jew or provide sufficient evidence of having Jewish ancestry.
=== South Africa === Saudi Arabia supplies most of South Africa's fuel. The South African Government has said that there was no shortage of fuel in the country, but prices have increased and some petrol stations have introduced their own rationing of diesel. With more traffic potentially taking the route around the Cape of Good Hope, and ships needing to fuel along the African coast, some ports such as Walvis Bay, Cape Town, and Durban may come under increased pressure, but also benefit from the diversion.
== Verification status removals == On March 23, 2023, Twitter announced that on April 1, 2023, it would begin winding down its legacy verification program and removing legacy verified checkmarks. The New York Times reported that exceptions would be made for Twitter's top 500 advertisers and its 10,000 most-followed organizations that had been previously verified. BuzzFeed News reported that multiple news organizations like The New York Times, The Washington Post and The Los Angeles Times had no plans to pay for Twitter's "Verified Organizations" service nor would they reimburse reporters for having Twitter Blue. Similarly, Axios reported that White House digital strategy director Rob Flaherty sent an internal email to staffers saying "[t]here are ongoing trials for the program that we are monitoring, but we will not enroll in it." Twitter did not immediately begin removing checkmarks on April 1, 2023. The Washington Post reported that "[the removal] of verification badges is a largely manual process powered by a system prone to breaking" and "[i]n the past, there was no way to reliably remove badges at a bulk scale", according to former Twitter employees. Twitter also updated the language previously used to distinguish between legacy and Twitter Blue-verified users, merging them into a single description, and later unfollowed all legacy-verified accounts. On April 11, 2023, Musk announced the final date for removing legacy blue checkmarks to be April 20.
The submucosa (tela submucosa), or submucosal layer, is a thin layer of tissue in various organs of the gastrointestinal, respiratory, and genitourinary tracts. It is the layer of dense irregular connective tissue that supports the mucosa (mucous membrane) and joins it to the muscular layer, the bulk of overlying smooth muscle (fibers running circularly within layer of longitudinal muscle). The submucosa (sub- + mucosa) is to a mucous membrane what the subserosa (sub- + serosa) is to a serous membrane.
Sources: en.wikipedia.org
He strengthened the squad by signing Alexis Sánchez from Barcelona in July 2014, who started in the 2014 FA Community Shield that Arsenal won by beating Manchester City 3–0, and during the course of 2014–15, Wenger promoted Francis Coquelin and Héctor Bellerín into the first team. Wenger won his sixth FA Cup in May 2015, which placed him alongside George Ramsay as the most successful manager in the competition's history. Wenger guided the club to an improved third place in the league that season, and the club saw further improvement in the 2015–16 season as they finished as league runners-up, while retaining the FA Community Shield by defeating Chelsea 1–0.
When Eddy first met Quimby in Portland in October 1862, she had to be helped up the stairs to his consulting rooms. She spoke highly of him the following month in a letter to the Portland Evening Courier: "This truth which he opposes to the error of giving intelligence to matter and placing pain where it never placed itself ... changes the currents of the system to their normal action ..." In a second letter she offered to supply quotations from Quimby's "theory of Christ (not Jesus)." Between then and May 1864, Eddy returned to see Quimby several times, staying for weeks in Portland and visiting him daily. She wrote to him regularly, and composed a sonnet for him, "Mid light of science sits the sage profound." Eddy first used mental healing on a patient in March 1864, when one of Quimby's patients in Portland, Mary Ann Jarvis, suffered a relapse when she returned home to Warren, Maine. Eddy stayed with her for two months, giving Jarvis mental healing to ease a breathing problem, and writing to Quimby six times for absent treatment for herself. She called the latter "angel visits"; in one of her letters to Quimby, she said that she had seen him in her room. In April she gave a public lecture in Warren, contrasting mental healing with Spiritualism, entitled: "P. P. Quimby's Spiritual Science healing disease, as opposed to Deism or Rochester Rapping Spiritualism."
=== Schizosaccharomyces yeast === Several species in the genus Schizosaccharomyces use L-malic acid, and enologists have been exploring the potential of using this wine yeast for deacidifying wines instead of the traditional route of malolactic fermentation with bacteria. However, early results with Schizosaccharomyces pombe have shown a tendency of the yeast to produce off odors and unpleasant sensory characteristics in the wine. In recent years, enologists have been experimenting with a mutant strain of Schizosaccharomyces malidevorans that has so far been shown to produce less potential wine flaws and off odors.
=== Hemorrhage and trauma === Synthetic platelets have the potential to aid trauma care by rapidly enhancing hemostasis, reducing blood loss, and improving survival outcomes in hemorrhagic injuries. SynthoPlate, a liposome-based synthetic platelet surrogate, has been designed to mimic both platelet adhesion and aggregation mechanisms through heteromultivalent surface modifications. Studies have demonstrated that SynthoPlate maintains stability after sterilization via filtration and E-beam irradiation and remains viable during long-term suspension storage. In a porcine arterial injury model, a single intravenous dose of SynthoPlate resulted in 100% survival during the first hour post-injury, compared to 0% in saline-treated controls. Unlike unmodified liposomes, SynthoPlate was shown to enhance hemostasis while stabilizing mean arterial pressure, reducing blood loss, and improving survival outcomes. These findings suggest that platelet-mimicking nanoparticles could serve as a viable transfusion alternative for hemorrhage management in pre-hospital and battlefield settings. Peptide-based nanoparticles (pNPs) have been studied for their potential in hemorrhage control by mimicking natural clot formation. In vitro experiments demonstrated that pNPs, when incubated with CD105 and red blood cells, formed stable artificial clots with fibrous networks similar to natural thrombi. These clots resisted enzymatic degradation, maintaining structural integrity unlike natural fibrin clots.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.